According to Benzinga Pro, Quest Diagnostics's peer group average for short interest as a percentage of float is 9.65%, which means the company has less short interest than most of its peers. Did you ...

This was the stock's second consecutive day of losses.

Mizuho analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $265 from $280 and keeps an Outperform rating on the shares ...

Read more about Cryptonews The price predictions on this page represent Cryptonews' market analysis based on available data and trends, but should not be considered as financial or investment advice.

Real time quote data is not available at this time.